Consensus EPS · Q2 2026
-$2.06
Consensus revenue · Q2 2026
$15.5M
Analysts
12
Expected report
Aug 5, 2026
What to watch
- Analyst ratings: Mixed
Analyst consensus
Based on estimates from 12 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | — | $15.5M | $250M |
| EPS | -$2.34 | -$2.06 | -$1.89 |
| EBITDA | -$681K | -$354.6K | -$28.2K |
| EBIT | -$681K | -$354.6K | -$28.2K |
| Net income | -$490.6M | -$404.6M | -$178.2M |
- Revenue$15.5M
- EPS-$2.06
- EBITDA-$354.6K
- EBIT-$354.6K
- Net income-$404.6M
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
Revision trends appear once we have collected at least two daily snapshots for this period.
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
Be the first to predict
No community consensus for Revolution Medicines (RVMD) Q2 2026 yet. Make a prediction to start the crowd forecast.
Analyst price target
Based on price targets from 5 analysts.
- Low
- $144.00
- Consensus
- $194.09
- Median
- $195.00
- High
- $235.00
- Current
- $187.53
- Upside
- +3.5%
Upside calculated vs most recent trading price of $187.53.
Consensus across all covering analysts. See the ranking ›
Analyst ratings
Consensus: Buy — based on 23 analyst ratings.
24-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 23, 2026 | Wedbush | maintain | Outperform | Outperform |
| Jul 20, 2026 | Needham | maintain | Buy | Buy |
| Jul 9, 2026 | Guggenheim | maintain | Buy | Buy |
| Jul 6, 2026 | Mizuho | maintain | Outperform | Outperform |
| Jul 6, 2026 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jul 2, 2026 | Wedbush | maintain | Outperform | Outperform |
| Jun 30, 2026 | Truist Securities | maintain | Buy | Buy |
| Jun 29, 2026 | Needham | maintain | Buy | Buy |
| Jun 10, 2026 | Evercore ISI Group | maintain | Outperform | Outperform |
| Jun 2, 2026 | RBC Capital | maintain | Outperform | Outperform |
- Jul 23, 2026WedbushOutperform
- Jul 20, 2026NeedhamBuy
- Jul 9, 2026GuggenheimBuy
- Jul 6, 2026MizuhoOutperform
- Jul 6, 2026HC Wainwright & Co.Buy
- Jul 2, 2026WedbushOutperform
- Jun 30, 2026Truist SecuritiesBuy
- Jun 29, 2026NeedhamBuy
- Jun 10, 2026Evercore ISI GroupOutperform
- Jun 2, 2026RBC CapitalOutperform
Frequently asked questions
Revolution Medicines (RVMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.